Gates Capital Management, L.P. and related reporting persons filed Amendment No. 5 to a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in MasterBrand, Inc. common stock as of September 30, 2026.
Medicus Pharma Ltd. filed a current report on November 13, 2026, disclosing a debt-to-equity exchange with Streeterville Capital, LLC and a registered direct offering that raised approximately $3.0 million in gross proceeds.
MARA Holdings, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing that its subsidiary MARA USA Corporation has commenced a private offering of $185 million aggregate principal amount of 8.750% Senior Secured Notes due 2032 issued by Long Ridge Energy …
YYForce Inc. issued a press release on November 16, 2026, outlining five operating priorities spanning frontline staffing, facility management software, commercial robotics, humanoid robotics development, and financial discipline.
Tyson Foods, Inc. filed a Form 8-K on November 16, 2026, disclosing that it issued a press release and financial results presentation covering its fourth quarter and fiscal year ended October 3, 2026.
MapLight Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $51.6 million for the three months ended September 30, 2026, and $172.5 million for the nine months …
Fusion Fuel Green PLC filed a Form 6-K with the U.S. Securities and Exchange Commission on November 16, 2026, furnishing a press release covering third-quarter and nine-month financial results for its majority-owned subsidiary Quality Industrial Corp. and providing operational updates on Al Shola Gas …
Agape ATP Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting continued net losses from continuing operations and a sharp decline in quarterly revenue.
FitLife Brands, Inc. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026, and reporting net income of $1.571 million for the quarter and $5.241 million for the nine-month period.
CNS Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $2.499 million for the third quarter and cash and cash equivalents of $17.212 million at …